Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Artelo Biosciences ( (ARTL) ) is now available.
On October 15, 2025, Artelo Biosciences entered into a cooperation agreement with Daniel S. Farb and his affiliates, leading to the withdrawal of Farb’s board nominations at the 2025 annual meeting. The agreement includes standstill restrictions and voting commitments by the Farb Parties, impacting their shareholding and voting rights, and establishes mutual non-disparagement and release of claims between the parties.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences operates in the biotechnology industry, focusing on the development of therapeutics targeting lipid signaling pathways.
Average Trading Volume: 112,495
Technical Sentiment Signal: Sell
Current Market Cap: $4.59M
Learn more about ARTL stock on TipRanks’ Stock Analysis page.